Trial · NCT07878091
A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
NCT07878091, Phase 2, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Trials, record NCT07878091. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07878091
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
- NCT number
- NCT07878091
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Conditions
- Metabolic Dysfunction-Associated Steatoic Liver Disease
- Interventions
- Kylo 0603 Capsule 8mg, Kylo 0603 Capsule 12mg, Kylo 0603 Capsule 16mg, Kylo 0603 Capsule Placebo
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percentage change from baseline in liver fat content | After 12 weeks of treatment. | The percentage change from baseline in liver fat content assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) after 12 weeks of treatment. |
| Secondary | Change in Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFFZ) | After 12 weeks of treatment | Change from baseline in MRI-PDFF |
| Secondary | Proportion of participants with a decrease in Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) | After 12 weeks of treatment. | Proportion of Study Participants with ≥30% and 50% reduction in MRI-PDFF from baseline |
| Secondary | Change from baseline in liver stiffness measurement (LSM) | After 12 weeks of treatment. | |
| Secondary | Change in low-density lipoprotein cholesterol (LDL-c) | After 12 weeks of treatment. | |
| Secondary | Change from baseline in alanine aminotransferase (ALT) | After 12 weeks of treatment. | |
| Secondary | High-sensitivity C-reactive protein (hsCRP) | After 12 weeks of treatment. | |
| Secondary | Change from baseline in cytokeratin-18 (CK-18) | After 12 weeks of treatment. | |
| Secondary | Change in body mass index [BMI] | After 12 weeks of treatment. | |
| Secondary | Change in the level of insulin resistance | After 12 weeks of treatment. | Change from baseline in the level of insulin resistance: assessed by the Homeostasis Model Assessment (HOMA-IR) |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07878091
GET https://conductscience.org/api/trials/v1/NCT07878091/registered?page=2